Search

Comella, C, RA Hauser, SH Isaacson, D Truong, O Oguh, J Hui, ES Molho, et al. 2022. “Efficacy and Safety of Two IncobotulinumtoxinA Injection Intervals in Cervical Dystonia Patients With Inadequate Benefit from Standard Injection Intervals of Botulinum Toxin: Phase 4, Open-Label, Randomized, Noninferiority Study. 2022 Mar 14;”. Clin Park Relat Disord.

Pagano, G, RA Hauser, KI Taylor, J Anzures-Cabrera, M Marchesi, T Simuni, K Marek, RB Postuma, N Pavese, and . 2022. “Trial of Prasinezumab in Early-Stage Parkinson’s Disease. 2022 Aug 4;387(5):421-432. Doi: 10.1056/NEJMoa2202867. PMID: 35921451”. N Engl J Med.

Hauser, RA, AJ Espay, AL Ellenbogen, HH Fernandez, SH Isaacson, PA LeWitt, WG Ondo, et al. 2023. “IPX203 versus Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson’s Disease: The RISE-PD Randomized Clinical Trial of Trial. 2023 Oct 1;80(10):1062-1069. Doi: 10.1001/Jamaneurol.2023.2679. PMID: 37578800”. JAMA Neurol.

Trosch, RM, CL Comella, RA Hauser, SN Caroff, WG Ondo, AC Shillington, BJ LaChappelle, CU Correll, and JH Friedman. 2024. “The Clinician’s Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia.”. J Clin Psychiatry. 2024 Jan 24;85(1):23m14886. Doi: 10.4088/JCP.23m14886. PMID: 38270545.

Fernandez, HH, EA Macklin, RA Hauser, KL Chou, YO Cakmak, B Ozsoy, S Fahn, and Parkinson Study Group. 2024. “Intrinsic Auricular Muscle Zone Stimulation for Parkinson Disease: The EARSTIM-PD Phase II Multi-Center Pilot Study Results”. . Parkinsonism Relat Disord. 2024 Apr;121:105959. Doi: 10.1016/J.Parkreldis.2023.105959. Epub 2023 Dec 27. PMID: 38246833.

Aradi, S, and R Hauser. 2024. “Current Use of Neurotoxins for Alleviating Symptoms of Cervical Dystonia.”. Expert Review of Neurotherapeutics. June 2024 DOI: 10.1080/14737175.2024.2368638.

Hauser, RA, WG Ondo, L Zhang, A Bowling, B Navia, E Pappert, and SH Isaacson. 2023. “Study Investigators. Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary? 2023 Mar 22. Doi: 10.3233/JPD-223537. 2023;13(3):403-414. PMID: 36970914”. J Parkinsons Dis.

Morinan, G, RA Hauser, A Schrag, J Tang, J O’Keeffe, and MDS-NMS Scale Development Study Group. 2022. “Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search. Parkinsons Dis. 2022 Jun 7;2022:2920255. Doi: 10.1155/2022/2920255. ECollection 2022. PMID: 35711334”. Parkinsons Dis.

Hauser, RA, H Barkay, HH Fernandez, J Jimenez-Shahed, SA Factor, N Gross, L Marinelli, et al. 2024. “Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.”. J Clin Psychopharmacol. 2024 Jul-Aug 01;44(4):386-396. Doi: 10.1097/JCP.0000000000001885. Epub 2024 Jun 21.PMID: 38901008.

Hauser, RA, AJ Espay, R Dhall, S Thakkar, L Cloud, L Zietlin, G Banisadr, S Fisher, and H Visser. 2024. “Safety and Efficacy of IPX203 in Parkinson’s Disease: The RISE-PD Open-Label Extension Study.”. Mov Disord. 2024 Feb;39(2):428-432. Doi: 10.1002/Mds.29685. Epub 2023 Dec 18. PMID: 38111267.